Objective To analyze the clinical effect of sevelamer carbonate tablets in the treatment of hyperphosphatemia in maintenance hemodialysis (MHD) patients. Methods 225 MHD patients with hyperphosphatemia were divided into Group A (n=75,treated with sevelamer carbonate tablets),Group B (n=75,treated with lanthanum carbonate chewable tablets) and Group C[n=75,treated with calcium carbonate D3 chewable tablets (Ⅱ)]according to random number method. Comparison was made on efficacy,and the blood calcium,blood phosphorus,calcium-phosphorus product,the level of intact parathyroid hormone (iPTH) before and after treatment,and the occurrence of adverse reactions among the three groups. Results After treatment,the effective rate of Group A was 86.67％,Group B was 69.33％ and Froup C was 21.33％. The effective rate of Group A and Group B was higher than that of Group C,and the effective rate of Group A was higher than that of Group B. The difference was statistically significant (P<0.05). In group A,the blood calcium,blood phosphorus,calcium-phosphorus product after 3 and 6 months of treatment were[(1.98±0.30) and (1.97±0.20) mmol/L],[(2.11±0.15) and (1.48±0.13) mmol/L],[(58.36±5.10) and (55.28±3.72) mg/dl];in group B,the blood calcium,blood phosphorus,calcium-phosphorus product after 3 and 6 months of treatment were[(1.99±0.20) and (1.98±0.23) mmol/L],[(2.26±0.18) and (1.80±0.15) mmol/L],[(60.84±5.37) and (59.56±5.31) mg/dl];in group C,the blood calcium,blood phosphorus,calcium and phosphorus product after 3 and 6 months of treatment were[(2.11±0.32) and (2.20±0.25) mmol/L],[(2.45±0.12) and (2.35±0.18) mmol/L],[(64.15±6.61) and (65.41±6.83) mg/dl]. The blood calcium of Group A and Group B after 3 and 6 months of treatment was lower than that of Group C,and the blood calcium of Group C after 3 and 6 months of treatment was higher than that before treatment. The difference was statistically significant (P<0.05). The blood phosphorus and calcium-phosphorus product in Group A and Group B after 3 and 6 months of treatment were lower than those before treatment in this group and those in Group C,and the blood phosphorus and calcium-phosphorus product in Group A was lower than that in Group B. The difference was statistically significant (P<0.05). There was no significant difference in iPTH among the three groups before and after treatment (P>0.05). The incidence of adverse reactions was 0 in Group A,17.33％(13/75) in Group B,and 24.00％(18/75) in Group C. The incidence of adverse reactions in Group A was lower than that in Group B and Group C,and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between Group B and Group C (P>0.05). Conclusion Sevelamer carbonate tablets can effectively reduce high phosphorus levels in MHD patients with hyperphosphatemia and has a relatively low incidence of adverse reactions.
维普
万方数据
